Ms. Celia Economides reports

AURINIA PHARMACEUTICALS ADDED TO THE NASDAQ BIOTECH INDEX

Aurinia Pharmaceuticals Inc. has been selected for addition to the Nasdaq Biotechnology Index, which will become effective prior to market open on Monday, Dec. 18, 2017.

The Nasdaq Biotechnology Index is designed to track the performance of a set of Nasdaq-listed securities that are classified as either biotechnology or pharmaceutical according to the industry classification benchmark. The Nasdaq Biotechnology Index is reranked annually. The Nasdaq Biotechnology Index is the basis for the iShares Nasdaq Biotechnology Index Fund, which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Nasdaq Biotechnology Index. In addition, options based on the iShares Nasdaq Biotechnology Index Fund trade on various exchanges. For more information about the Nasdaq Biotechnology Index please visit the Nasdaq website.

Additionally, Aurinia was recently added to the MSCI Global Small Cap Indexes, which went into effect at close of Nov. 30, 2017. Canada added 17 securities and deleted seven securities from MSCI Global Small Cap indexes.

About Aurinia Pharmaceuticals Inc.

Aurinia is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations who are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of LN. The company is headquartered in Victoria, B.C., and focuses its development efforts globally.

We seek Safe Harbor.